News
The randomized, single-blind, controlled, multi-center Phase I clinical trial of the INTERCEPT red blood cell system is expected to enroll approximately 28 healthy subjects. Each subject will ...
Cerus currently markets the INTERCEPT Blood System for both platelets and plasma in Europe and the Middle East. The INTERCEPT red blood cell system is currently in clinical development.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback